Skip to content
Chymopapain
Chymodiactin (chymopapain) is an unknown pharmaceutical. Chymopapain was first approved as Chymodiactin on 1982-11-10.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Chymopapain
Tradename
Proper name
Company
Number
Date
Products
ChymodiactinchymopapainDisCure MedicalN-18663 DISCN1982-11-10
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M09: Other drugs for disorders of the musculo-skeletal system in atc
— M09A: Other drugs for disorders of the musculo-skeletal system in atc
— M09AB: Enzymes for disorders of the musculo-skeletal system
— M09AB01: Chymopapain
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients————2—2
Diabetic neuropathiesD003929EFO_1000783———1—1
Diabetic retinopathyD003930EFO_0003770———1—1
Chronic renal insufficiencyD051436N18———1—1
HyperphosphatemiaD054559HP_0002905———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_0003124—12—14
Cardiovascular diseasesD002318EFO_0000319I98—13——4
Coronary diseaseD003327—13——4
Myocardial ischemiaD017202EFO_1001375I20-I25—13——4
Heart diseasesD006331EFO_0003777I51.9—13——4
Multiple sclerosisD009103EFO_0003885G351—1——2
Graves diseaseD006111EFO_0004237E05.0——1—12
HyperthyroidismD006980E05.9——1——1
Myocardial infarctionD009203EFO_0000612I21——1——1
Hyperlipoproteinemia type iiD006938EFO_0004911E78.00——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
Short bowel syndromeD012778—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MicrobiotaD0643071————1
Renal insufficiencyD051437HP_0000083N191————1
Biliary liver cirrhosisD008105K74.31————1
Alagille syndromeD016738Q44.71————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperlipidemiasD006949EFO_0003774E78.5————11
Carotid stenosisD016893————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHYMOPAPAIN
INNchymopapain
Description
Chymopapain (EC 3.4.22.6, chymopapain A, chymopapain B, chymopapain S, brand name Chymodiactin) is a proteolytic enzyme isolated from the latex of papaya (Carica papaya). It is a cysteine protease which belongs to the papain-like protease (PLCP) group. Because of its proteolytic activity, it is the main molecule in the process of chemonucleolysis, used in some procedures like the treatment of herniated lower lumbar discs in the spine by a nonsurgical method.
Classification
Protein
Drug class—
Image (chem structure or protein)CHYMOPAPAIN
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB1YAL
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201626
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID1UK146T40N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 736 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,908 adverse events reported
View more details